Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
Cancer Chemother Pharmacol. 2011 Aug;68(2):309-16. doi: 10.1007/s00280-010-1480-0. Epub 2010 Oct 22.
M30 and M65 are different circulating fragments of cytokeratin 18. They release during apoptotic cell death, so it is believed that they reflect cell death of epithelial tumors. The aim of this study was to determine the prognostic value of plasma M30 and M65 levels in predicting of survival for patients with advanced gastric cancer compare with healthy controls.
Thirty-four patients with advanced gastric cancer and thirty-two healthy controls were included. Plasma M30 and M65 values were measured by quantitative ELISA method.
The median age of patients and control groups was 60 and 56 years, respectively. No difference was detected between patient and control groups with respect to plasma median M30 values (390.4 vs. 270.7 U/l, respectively, P = 0.10). The median plasma M65 values of patients were significantly higher than those of control group (1232.1 vs. 580.1 U/l, P < 0.001). The best cut-off values for plasma M30 and M65 for predicting progression-free survival (PFS) were 277.7 and 1434.9 U/l in ROC analysis. The patients whose plasma M30 values were higher than 277.7 U/l had worse PFS than patients with plasma M30 value <277.7 U/l (8.9 vs. 11.2, respectively, P = 0.01). The median PFS of patients whose M65 levels lower than or equal to 1434.9 U/l was better than that of patients whose M65 levels were >1434.9 U/l (12.4 vs. 10.4, respectively, P = 0.04). But plasma M30 and M65 level in patient group were not found to be an important prognostic factor for PFS in the multivariate analysis.
These results showed that plasma M65 values were significantly elevated in patients with advanced gastric cancer compared to healthy people. Moreover, both increased plasma M30 and M65 levels can predict PFS in patients with gastric cancer.
M30 和 M65 是细胞角蛋白 18 的不同循环片段。它们在细胞凋亡死亡时释放，因此人们认为它们反映了上皮肿瘤的细胞死亡。本研究的目的是确定血浆 M30 和 M65 水平在预测晚期胃癌患者生存方面的预后价值，并与健康对照组进行比较。
纳入 34 例晚期胃癌患者和 32 名健康对照者。采用定量 ELISA 法测定血浆 M30 和 M65 值。
患者和对照组的中位年龄分别为 60 岁和 56 岁。患者和对照组之间的血浆中位 M30 值无差异（分别为 390.4 和 270.7 U/l，P=0.10）。患者的血浆 M65 值中位数明显高于对照组（1232.1 和 580.1 U/l，P<0.001）。ROC 分析显示，预测无进展生存期（PFS）的血浆 M30 和 M65 的最佳截断值分别为 277.7 和 1434.9 U/l。血浆 M30 值高于 277.7 U/l 的患者 PFS 较血浆 M30 值<277.7 U/l 的患者差（分别为 8.9 和 11.2，P=0.01）。M65 水平低于或等于 1434.9 U/l 的患者中位 PFS 优于 M65 水平>1434.9 U/l 的患者（分别为 12.4 和 10.4，P=0.04）。但在多因素分析中，患者组的血浆 M30 和 M65 水平未被发现是 PFS 的重要预后因素。
这些结果表明，与健康人相比，晚期胃癌患者的血浆 M65 值显著升高。此外，血浆 M30 和 M65 水平升高均可预测胃癌患者的 PFS。
